269 related articles for article (PubMed ID: 38137005)
41. Hypermorphic mutation of phospholipase C, γ2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation.
Liu TM; Woyach JA; Zhong Y; Lozanski A; Lozanski G; Dong S; Strattan E; Lehman A; Zhang X; Jones JA; Flynn J; Andritsos LA; Maddocks K; Jaglowski SM; Blum KA; Byrd JC; Dubovsky JA; Johnson AJ
Blood; 2015 Jul; 126(1):61-8. PubMed ID: 25972157
[TBL] [Abstract][Full Text] [Related]
42. Bruton's tyrosine kinase inhibitors: first and second generation agents for patients with Chronic Lymphocytic Leukemia (CLL).
Thompson PA; Burger JA
Expert Opin Investig Drugs; 2018 Jan; 27(1):31-42. PubMed ID: 29125406
[TBL] [Abstract][Full Text] [Related]
43. Bruton tyrosine kinase inhibition in chronic lymphocytic leukemia.
Maddocks K; Jones JA
Semin Oncol; 2016 Apr; 43(2):251-9. PubMed ID: 27040703
[TBL] [Abstract][Full Text] [Related]
44. Bruton's tyrosine kinase mediated signaling enhances leukemogenesis in a mouse model for chronic lymphocytic leukemia.
Kil LP; de Bruijn MJ; van Hulst JA; Langerak AW; Yuvaraj S; Hendriks RW
Am J Blood Res; 2013; 3(1):71-83. PubMed ID: 23359016
[TBL] [Abstract][Full Text] [Related]
45. Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia.
Mato AR; Woyach JA; Brown JR; Ghia P; Patel K; Eyre TA; Munir T; Lech-Maranda E; Lamanna N; Tam CS; Shah NN; Coombs CC; Ujjani CS; Fakhri B; Cheah CY; Patel MR; Alencar AJ; Cohen JB; Gerson JN; Flinn IW; Ma S; Jagadeesh D; Rhodes JM; Hernandez-Ilizaliturri F; Zinzani PL; Seymour JF; Balbas M; Nair B; Abada P; Wang C; Ruppert AS; Wang D; Tsai DE; Wierda WG; Jurczak W
N Engl J Med; 2023 Jul; 389(1):33-44. PubMed ID: 37407001
[TBL] [Abstract][Full Text] [Related]
46. BTK inhibitors in chronic lymphocytic leukemia: a glimpse to the future.
Spaargaren M; de Rooij MF; Kater AP; Eldering E
Oncogene; 2015 May; 34(19):2426-36. PubMed ID: 24954503
[TBL] [Abstract][Full Text] [Related]
47. Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia.
Deng J; Isik E; Fernandes SM; Brown JR; Letai A; Davids MS
Leukemia; 2017 Oct; 31(10):2075-2084. PubMed ID: 28111464
[TBL] [Abstract][Full Text] [Related]
48. Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies.
Aw A; Brown JR
Drugs Aging; 2017 Jul; 34(7):509-527. PubMed ID: 28536906
[TBL] [Abstract][Full Text] [Related]
49. Dermatological Toxicities of Bruton's Tyrosine Kinase Inhibitors.
Sibaud V; Beylot-Barry M; Protin C; Vigarios E; Recher C; Ysebaert L
Am J Clin Dermatol; 2020 Dec; 21(6):799-812. PubMed ID: 32613545
[TBL] [Abstract][Full Text] [Related]
50. Non-Covalent Bruton's Tyrosine Kinase Inhibitors in the Treatment of Chronic Lymphocytic Leukemia.
Montoya S; Thompson MC
Cancers (Basel); 2023 Jul; 15(14):. PubMed ID: 37509309
[TBL] [Abstract][Full Text] [Related]
51. Overcoming resistance to targeted therapies in chronic lymphocytic leukemia.
Skånland SS; Mato AR
Blood Adv; 2021 Jan; 5(1):334-343. PubMed ID: 33570649
[TBL] [Abstract][Full Text] [Related]
52. Comparison of Acalabrutinib, A Selective Bruton Tyrosine Kinase Inhibitor, with Ibrutinib in Chronic Lymphocytic Leukemia Cells.
Patel V; Balakrishnan K; Bibikova E; Ayres M; Keating MJ; Wierda WG; Gandhi V
Clin Cancer Res; 2017 Jul; 23(14):3734-3743. PubMed ID: 28034907
[No Abstract] [Full Text] [Related]
53. Resistance to BTK inhibition by ibrutinib can be overcome by preventing FOXO3a nuclear export and PI3K/AKT activation in B-cell lymphoid malignancies.
Kapoor I; Li Y; Sharma A; Zhu H; Bodo J; Xu W; Hsi ED; Hill BT; Almasan A
Cell Death Dis; 2019 Dec; 10(12):924. PubMed ID: 31801949
[TBL] [Abstract][Full Text] [Related]
54. Expression of functional sphingosine-1 phosphate receptor-1 is reduced by B cell receptor signaling and increased by inhibition of PI3 kinase δ but not SYK or BTK in chronic lymphocytic leukemia cells.
Till KJ; Pettitt AR; Slupsky JR
J Immunol; 2015 Mar; 194(5):2439-46. PubMed ID: 25632006
[TBL] [Abstract][Full Text] [Related]
55. Targeted Axl Inhibition Primes Chronic Lymphocytic Leukemia B Cells to Apoptosis and Shows Synergistic/Additive Effects in Combination with BTK Inhibitors.
Sinha S; Boysen J; Nelson M; Secreto C; Warner SL; Bearss DJ; Lesnick C; Shanafelt TD; Kay NE; Ghosh AK
Clin Cancer Res; 2015 May; 21(9):2115-26. PubMed ID: 25673699
[TBL] [Abstract][Full Text] [Related]
56. NRX-0492 degrades wild-type and C481 mutant BTK and demonstrates in vivo activity in CLL patient-derived xenografts.
Zhang D; Harris HM; Chen J; Judy J; James G; Kelly A; McIntosh J; Tenn-McClellan A; Ambing E; Tan YS; Lu H; Gajewski S; Clifton MC; Yung S; Robbins DW; Pirooznia M; Skånland SS; Gaglione E; Mhibik M; Underbayev C; Ahn IE; Sun C; Herman SEM; Noviski M; Wiestner A
Blood; 2023 Mar; 141(13):1584-1596. PubMed ID: 36375120
[TBL] [Abstract][Full Text] [Related]
57. Integrin Signaling Shaping BTK-Inhibitor Resistance.
Polcik L; Dannewitz Prosseda S; Pozzo F; Zucchetto A; Gattei V; Hartmann TN
Cells; 2022 Jul; 11(14):. PubMed ID: 35883678
[TBL] [Abstract][Full Text] [Related]
58. Revolution of Chronic Lymphocytic Leukemia Therapy: the Chemo-Free Treatment Paradigm.
Scheffold A; Stilgenbauer S
Curr Oncol Rep; 2020 Feb; 22(2):16. PubMed ID: 32025827
[TBL] [Abstract][Full Text] [Related]
59. Ibrutinib treatment of CLL: the cancer fights back.
Young RM; Staudt LM
Cancer Cell; 2014 Jul; 26(1):11-3. PubMed ID: 25026208
[TBL] [Abstract][Full Text] [Related]
60. Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL.
Sharma S; Galanina N; Guo A; Lee J; Kadri S; Van Slambrouck C; Long B; Wang W; Ming M; Furtado LV; Segal JP; Stock W; Venkataraman G; Tang WJ; Lu P; Wang YL
Oncotarget; 2016 Oct; 7(42):68833-68841. PubMed ID: 27626698
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
